BioArctic
BIOA | STO
Overview
Corporate Details
- ISIN(s):
- SE0010323303 (+1 more)
- LEI:
- 549300Y0OI2WVUNHLC33
- Country:
- Sweden
- Address:
- Warfvinges väg 35, 112 51 Stockholm
- Website:
- https://www.bioarctic.se/en/
- Sector:
- Health Care
- Industry:
- Biotechnology
Description
BioArctic is a Swedish research intensive biopharma company aimed at developing new treatments that address the causes of disorders that affect the Central Nervous System. These types of treatments are commonly referred to as “disease modifiers”. They affect the underlying disease pathology and can hopefully stop or significantly delay disease progression. This is a large paradigm shift from today’s symptom-oriented therapies. BioArctic’s proprietary technology platform, dedicated personnel, collaborations with leading academic research groups and the global pharma industry have made it possible to develop innovative treatments based on antibodies (immunotherapy) for neurodegenerative disorders. Our main research areas are Alzheimer’s disease and Parkinson’s disease where there are large unmet medical needs. Today there are no treatments that can stop or slow down the progression of these diseases.
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Filings
| Date | Filing | Language | Size | Actions |
|---|---|---|---|---|
| 2025-05-30 18:30 |
Declaration of Voting Results & Voting Rights Announcements
Number of shares and votes in BioArctic AB (publ) as of May 30, 2025
|
English | 163.0 KB | |
| 2025-05-30 18:30 |
Declaration of Voting Results & Voting Rights Announcements
Antal aktier och röster i BioArctic AB (publ) per den 30 maj 2025
|
Swedish | 159.1 KB | |
| 2025-05-22 18:19 |
Declaration of Voting Results & Voting Rights Announcements
Kommuniké från årsstämma i BioArctic AB (publ)
|
Swedish | 194.1 KB | |
| 2025-05-22 18:19 |
Declaration of Voting Results & Voting Rights Announcements
Bulletin from the Annual General Meeting in BioArctic AB (publ)
|
English | 192.8 KB | |
| 2025-05-22 15:15 |
Regulatory News Service
BioArctic receives positive opinion for Orphan Medicinal Product Designation in…
|
English | 172.1 KB | |
| 2025-05-22 15:15 |
Regulatory News Service
BioArctic erhåller positiv rekommendation för särläkemedelsklassificering i EU …
|
Swedish | 190.7 KB | |
| 2025-05-21 08:00 |
Earnings Release
|
Swedish | 14.5 MB | |
| 2025-05-21 08:00 |
Earnings Release
|
English | 14.5 MB | |
| 2025-05-15 06:00 |
Inside Information Statement
Eisai prognosticerar 76,5 miljarder JPY i försäljning av Leqembi® för bolagets …
|
Swedish | 247.5 KB | |
| 2025-05-15 06:00 |
Inside Information Statement
Eisai projects Leqembi® revenue to total JPY 76.5 billion for fiscal year 2025 …
|
English | 266.6 KB | |
| 2025-05-01 12:45 |
Earnings Release
Sales of Leqembi[®] totaled 14.7 billion yen in the first quarter 2025
|
English | 187.6 KB | |
| 2025-05-01 12:45 |
Earnings Release
Försäljningen av Leqembi[®] uppgick till 14,7 miljarder yen under det första kv…
|
Swedish | 190.4 KB | |
| 2025-04-22 20:00 |
Regulatory News Service
Notice of Annual General Meeting 2025 in BioArctic AB (publ)
|
English | 269.5 KB | |
| 2025-04-22 20:00 |
Regulatory News Service
Kallelse till årsstämma 2025 i BioArctic AB (publ)
|
Swedish | 308.1 KB | |
| 2025-04-22 20:00 |
Annual Report
|
Swedish | 8.2 MB |
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2025-02-13 | Gunilla Osswald | Other | Sell | 40,000 | 8,821,200.00 SEK |
| 2025-02-13 | Gunilla Osswald | Other | Other | 40,000 | 3,344,000.00 SEK |
| 2025-02-13 | Sten Mikael Moge | Other | Sell | 6,000 | 1,323,180.00 SEK |
| 2025-02-13 | Sten Mikael Moge | Other | Other | 6,000 | 501,600.00 SEK |
| 2025-02-13 | Johanna Margareta Fälting | Other | Sell | 1,500 | 330,795.00 SEK |
| 2025-02-13 | Johanna Margareta Fälting | Other | Other | 2,500 | 209,000.00 SEK |
| 2025-02-13 | Johanna Margareta Fälting | Other | Other | 1,500 | 125,400.00 SEK |
| 2025-01-10 | Mikael Smedeby | Other | Buy | 730 | 148,920.00 SEK |
| 2024-12-19 | Oskar Bosson | Other | Sell | 2,000 | 446,000.00 SEK |
| 2024-12-19 | Oskar Bosson | Other | Sell | 871 | 195,626.60 SEK |
Peer Companies
| Company | Country | Ticker | View | |
|---|---|---|---|---|
|
1NKEMIA | Spain | IKM | |
|
2cureX AB | Sweden | 2CUREX | |
|
4SC AG | Germany | VSC | |
|
Abera Bioscience AB | Sweden | ABERA | |
|
ABIONYX Pharma | France | ABNX | |
|
Abliva | Sweden | ABLI | |
|
AB Science | France | AB | |
|
Acticor Biotech | France | ALACT | |
|
Active Biotech | Sweden | ACTI | |
|
AcuCort AB | Sweden | ACUC |